Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics IncfiledCriticalCytomx Therapeutics Inc
Publication of AR105316A1publicationCriticalpatent/AR105316A1/en
La presente se refiere en general a anticuerpos que unen CD71, anticuerpos activables que se unen específicamente con CD71 y métodos de preparación y uso de estos anticuerpos anti-CD71 y anticuerpos activables anti-CD71 en una variedad de indicaciones terapéuticas, diagnósticas y preventivas.This refers in general to antibodies that bind CD71, activatable antibodies that specifically bind with CD71 and methods of preparing and using these anti-CD71 antibodies and activatable anti-CD71 antibodies in a variety of therapeutic, diagnostic and preventive indications.
ARP160101268A2015-05-042016-05-04
ANTIBODIES AGAINST THE TRANSFERRINE RECEIVER (ANTI-CD71), ANTI-CD71 ACTIVABLES ANTIBODIES AND THEIR METHODS OF USE
AR105316A1
(en)